Breast Cancer Research

乳腺癌研究进展 这一计划的重点是使用跨学科的方法来改善乳腺癌患者的治疗方案和结果。我们的计划希望通过更好地了解乳腺癌内在亚型的独特生物学和通过组织研究获得的乳腺癌异质性，以及其他生物标志物的发现和验证、风险因素评估和药物开发来实现这一目标，这将导致新的治疗试验和基于人群的研究。具体地说，我们的战略目标是：1)基础和流行病学科学发现与我们现有的理解相结合 在内在乳腺癌亚型中，2)成像和治疗方面的技术进步，3)在代表已知生物学亚型的模型中对有前景的治疗方法的小鼠模型测试，以及4)基于组织的发现和临床研究算法，用于合理的药物/组合研究，并采用包含嵌入的相关/研究性活组织研究的双向策略。 乳房计划非常适合促进基础科学成果在临床上的转化，因为它被大量整合到非常活跃的多学科临床和临床转换操作中，此外，该计划还与我们成熟的乳腺癌孢子基础设施无缝集成，其中包括临床医生、流行病学家和实验室科学家。项目研究人员的研究重点包括开发代表许多内在亚型的基因工程小鼠模型，使特定亚型的治疗策略能够在小鼠I期单元中进行测试(Perou，Sharpless)，开发一种可用于小动物和人类乳腺癌的新型成像技术(周，Pisano)，以及使用新的方案和试验设计(Carey，Anders)设计和执行临床试验；临床重点仍然是管理具有靶向试剂的特定亚型的前瞻性临床试验，以及嵌入分子签名和交叉试验验证的相关分析。在了解特定内在亚型的风险因素和分子生物学方面，来自医学院、公共卫生学院和遗传学学院的教师之间的合作取得了实质性进展，包括首次发现基底细胞样乳腺癌与非裔美国女性(Carey、Perou、MiDikan)有关。以人群为基础的卡罗莱纳乳腺癌研究III是这一计划的组成部分，正在检查特定亚型的风险因素和结果，重点是非裔美国女性。 补充性研究正在研究表观遗传和微环境的影响(Troester，Swift-Scanlan)，这些影响应该解决导致这些风险的“土壤”因素，老年肿瘤学的一个新项目正专注于乳腺肿瘤和宿主对治疗的反应的分子相关性(Muss，Sharpless)。 该计划由来自五个不同学校的24名成员和来自五个不同学科的临床医生组成。 2009年，乳房研究计划成员拥有56笔赠款和1230万美元(总成本)的年度外部资金，其中包括来自NCI的24笔赠款和740万美元(总成本)。

Breast Cancer Research This program is focused upon making improvements in breast cancer patient regimens and outcomes, using an interdisciplinary approach. Our program hopes to achieve this goal by utilizing an improved understanding of the distinct biology of the intrinsic subtypes of breast cancer and breast cancer heterogeneity obtained through tissue-based studies, with additional biomarker discovery and validation, risk factor appraisal, and drug development, which lead to new therapeutic trials and population-based studies. Specifically, our strategic goals are: 1) basic and epidemiologic science discovery integrated with our existing understanding of the intrinsic breast cancer subtypes, 2) technological advances in imaging and therapy, 3) mouse models testing of promising therapeutic approaches in models representing the known biological subtypes, and 4) tissue-based discovery and clinical research algorithms for rational drug/combination studies with bidirectional strategies of containing embedded correlative/research biopsy studies. The Breast program is well suited to foster translation of basic science findings Into the clinic and back again because it is heavily integrated into a very active multidisciplinary clinical and clinical-translational operation, n addition, this program is seamlessly integrated with our mature breast cancer SPORE infrastructure that includes clinicians, epidemiologists, and laboratory scientists. Highlights of research by program investigators include development of genetically engineered mouse models representing many of tine intrinsic subtypes allowing subtype-specific therapeutic strategies to be tested in the mouse phase I unit (Perou, Sharpless), the development of anotechnology-based and other novel imaging that can be applied to both small animal and human breast cancers (Zhou, Pisano), and the design and execution of clinical trials using novel regimens and trial designs (Carey, Anders); the clinical focus remains on the manage of subtype-specific prospective clinical trials with targeted agents and embedded correlative analysis of molecular signatures and cross-trial validations. Substantial progress in understanding the risk factors and molecular biology of specific intrinsic subtypes has come from collaborations between faculty from the schools of Medicine, Public Health, and Genetics, including the first identification of the association of basal-like breast cancer with African-American women (Carey, Perou, MiDikan). The population-based Carolina Breast Cancer Study III is integral to this program and is examining subtype-specific risk factors and outcomes with a focus upon African-American women. Complementary studies are examining epigenetic and microenvironmental influences (Troester, Swift-Scanlan) that should address the "soil" contributions to these risks, and a new program in geriatric oncology is focusing upon molecular correlates of breast tumor and host response to therapy (Muss, Sharpless). The Program consists of 24 members from five different schools and clinicians from five different disciplines. In 2009, Breast Research Program members held 56 grants and $12.3M (total cost) in annual extramural funding, including 24 grants and $7.4M (total costs) from the NCI.